Supernus (SUPN) announced that the company received Paragraph IV Notice Letters from third parties notifying Supernus that the third parties submitted abbreviated new drug applications for viloxazine extended-release capsules, eq. 100, 150, and 200 mg base. Supernus is currently reviewing the details of these notice letters and intends to vigorously enforce its intellectual property rights relating to Qelbree. The FDA’s Orange Book currently lists six issued United States patents as covering Qelbree, three that expire in September 2029, two that expire in February 2033 and one that expires in April 2035.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus partners with Busy Philipps for new campaign
- Supernus Pharmaceuticals’ Earnings Call: Growth Amid Challenges
- Supernus Pharmaceuticals Reports Q1 2025 Earnings Growth
- Optimistic Growth Prospects for Supernus Pharmaceuticals Driven by Qelbree’s Market Potential
- Supernus reports Q1 EPS (21c) vs. 0c last year